Published in Physician Law Weekly, October 5th, 2005
"One dose of a quadrivalent meningococcal conjugate (MC-4) vaccine elicits higher group C bactericidal responses in two-year olds than a U.S.-licensed quadrivalent polysaccharide (MPS-4) vaccine. The objective was to assess immunogenicity and persistence of serum antibody to capsular groups A, Y, and W-135 in two-year old children immunized with MC-4 vaccine. Measurement of antibody responses in sera from a multicenter randomized trial comparing MC-4 and MPS-4 vaccines," scientists in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2005-10-05)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.